Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.

Huang R, Langdon SP, Tse M, Mullen P, Um IH, Faratian D, Harrison DJ.

Oncotarget. 2016 Jan 26;7(4):4695-711. doi: 10.18632/oncotarget.6618.

2.

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers.

Briffa R, Um I, Faratian D, Zhou Y, Turnbull AK, Langdon SP, Harrison DJ.

PLoS One. 2015 Dec 17;10(12):e0144708. doi: 10.1371/journal.pone.0144708. eCollection 2015.

3.

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis.

Verleyen W, Langdon SP, Faratian D, Harrison DJ, Smith VA.

Sci Rep. 2015 Oct 27;5:15563. doi: 10.1038/srep15563.

4.

Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.

5.

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T, Geller MA, Langdon SP.

Gynecol Oncol. 2013 Nov;131(2):368-73. doi: 10.1016/j.ygyno.2013.07.099. Epub 2013 Jul 30.

PMID:
23911795
6.

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.

Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, Gourley C, Faratian D.

Br J Cancer. 2013 May 28;108(10):2039-44. doi: 10.1038/bjc.2013.199. Epub 2013 May 7.

7.

Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis.

Lucking AJ, Gibson KR, Paterson EE, Faratian D, Ludlam CA, Boon NA, Fox KA, Newby DE.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):1105-11. doi: 10.1161/ATVBAHA.112.300395. Epub 2013 Mar 7.

8.

The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers.

O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M, Faratian D, Powles T, Harrison DJ, Stewart GD.

J Vis Exp. 2013 Jan 22;(71). pii: 50221. doi: 10.3791/50221.

9.

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.

Endocr Relat Cancer. 2013 Feb 18;20(1):123-36. doi: 10.1530/ERC-12-0192. Print 2013 Feb.

10.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
11.

Molecular pathology in therapeutics: where are we now, and where are we going?

Harrison DJ, Faratian D.

Curr Drug Targets. 2012 Nov;13(12):1473-4. No abstract available.

PMID:
22974390
12.

KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Moleirinho S, Chang N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA.

Oncogene. 2013 Apr 4;32(14):1821-30. doi: 10.1038/onc.2012.196. Epub 2012 May 21.

PMID:
22614006
13.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Br J Cancer. 2012 May 22;106(11):1779-89. doi: 10.1038/bjc.2012.176. Epub 2012 May 1.

14.

Diversity of matriptase expression level and function in breast cancer.

Welman A, Sproul D, Mullen P, Muir M, Kinnaird AR, Harrison DJ, Faratian D, Brunton VG, Frame MC.

PLoS One. 2012;7(4):e34182. doi: 10.1371/journal.pone.0034182. Epub 2012 Apr 13.

15.

HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.

McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D.

J Clin Pathol. 2012 Jul;65(7):670-1; author reply 671-2. doi: 10.1136/jclinpath-2011-200616. Epub 2012 Mar 12. No abstract available.

PMID:
22412045
16.

The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma.

O'Mahony FC, Faratian D, Varley J, Nanda J, Theodoulou M, Riddick AC, Harrison DJ, Stewart GD.

PLoS One. 2012;7(2):e31557. doi: 10.1371/journal.pone.0031557. Epub 2012 Feb 21.

17.

Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer.

Sabine VS, Faratian D, Kirkegaard-Clausen T, Bartlett JM.

Histopathology. 2012 Jan;60(2):369-71. doi: 10.1111/j.1365-2559.2011.04024.x. Epub 2011 Dec 14. No abstract available.

PMID:
22168172
18.

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, Harrison DJ, Goryanin I.

Eur J Pharm Sci. 2012 Jul 16;46(4):244-58. doi: 10.1016/j.ejps.2011.10.026. Epub 2011 Nov 9.

19.

Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.

Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, Harrison DJ.

J Vis Exp. 2011 Oct 25;(56):e3334. doi: 10.3791/3334.

20.

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, Langdon SP.

BMC Cancer. 2011 Nov 3;11:476. doi: 10.1186/1471-2407-11-476.

21.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.

Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.

PMID:
21996585
22.

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP, Harrison DJ.

PLoS One. 2011;6(8):e23772. doi: 10.1371/journal.pone.0023772. Epub 2011 Aug 31.

23.

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.

van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen PJ, van de Velde CJ, Bartlett JM.

Breast Cancer Res Treat. 2012 May;133(1):49-59. doi: 10.1007/s10549-011-1684-y. Epub 2011 Jul 28.

PMID:
21796367
24.

Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer.

Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E.

Clin Exp Metastasis. 2011 Dec;28(8):811-8. doi: 10.1007/s10585-011-9412-x. Epub 2011 Jul 26.

PMID:
21789718
25.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

26.

What can molecular pathology contribute to the management of renal cell carcinoma?

Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D.

Nat Rev Urol. 2011 May;8(5):255-65. doi: 10.1038/nrurol.2011.43. Epub 2011 Apr 12. Review.

PMID:
21487387
27.

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

Faluyi OO, Gourley C, Smyth JF, Faratian D, Williams AR, Rye T, Rye R, Stewart M, Mackean MJ.

Int J Gynecol Cancer. 2010 Dec;20(9):1511-7.

PMID:
21370594
28.

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ.

Eur J Cancer. 2011 Jun;47(9):1420-31. doi: 10.1016/j.ejca.2011.01.014. Epub 2011 Feb 18.

PMID:
21334202
29.

Systems pathology.

Faratian D.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S4. doi: 10.1186/bcr2733. No abstract available.

30.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ.

Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14.

PMID:
20951800
31.

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.

Breast Cancer Res Treat. 2011 Aug;128(3):725-34. doi: 10.1007/s10549-010-0967-z. Epub 2010 Oct 13.

PMID:
20941539
32.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ.

Cancer Res. 2010 Nov 15;70(22):9391-401. doi: 10.1158/0008-5472.CAN-10-0911. Epub 2010 Sep 21.

33.

Cancer systems biology.

Faratian D, Bown JL, Smith VA, Langdon SP, Harrison DJ.

Methods Mol Biol. 2010;662:245-63. doi: 10.1007/978-1-60761-800-3_12. Review.

PMID:
20824475
34.

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk.

Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, Quinn JA, Edward M, Meehan RR, Evans EE, Langdon SP, Harrison DJ.

Br J Cancer. 2010 Jul 27;103(3):401-10. doi: 10.1038/sj.bjc.6605763. Epub 2010 Jul 13.

35.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.

Taylor KJ, Sims AH, Liang L, Faratian D, Muir M, Walker G, Kuske B, Dixon JM, Cameron DA, Harrison DJ, Langdon SP.

Breast Cancer Res. 2010;12(3):R39. doi: 10.1186/bcr2593. Epub 2010 Jun 22.

36.

Pertuzumab for the treatment of ovarian cancer.

Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ.

Expert Opin Biol Ther. 2010 Jul;10(7):1113-20. doi: 10.1517/14712598.2010.487062. Review.

PMID:
20465533
37.

COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients.

van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM.

Breast Cancer Res Treat. 2011 Feb;125(3):671-85. doi: 10.1007/s10549-010-0854-7. Epub 2010 Apr 1.

PMID:
20358279
38.

Reply to: discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the 'self (stem cell)-seeding' nature of breast cancer disease?

Faratian D, Aitken SJ, Thomas JS, Langdon SP, Harrison DJ.

Ann Oncol. 2010 Jun;21(6):1375. doi: 10.1093/annonc/mdq046. Epub 2010 Mar 9. No abstract available.

PMID:
20215137
39.

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.

Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JM.

Histopathology. 2009 Nov;55(5):587-93. doi: 10.1111/j.1365-2559.2009.03419.x.

PMID:
19912364
40.

The importance of growth factors and steroid hormones in ovarian cancer.

Langdon SP, Faratian D, Harrison DJ.

Onkologie. 2009 Nov;32(11):623-4. doi: 10.1159/000246764. Epub 2009 Oct 16. No abstract available.

41.

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D.

Ann Oncol. 2010 Jun;21(6):1254-61. doi: 10.1093/annonc/mdp427. Epub 2009 Oct 25.

PMID:
19858088
42.

How can systems pathology help us personalize cancer therapy?

Faratian D, Langdon SP, Harrison DJ.

Discov Med. 2009 Aug;8(41):81-6.

43.

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP.

Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8.

44.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

45.

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ.

Cancer Res. 2009 Aug 15;69(16):6713-20. doi: 10.1158/0008-5472.CAN-09-0777. Epub 2009 Jul 28.

46.

Systems pathology--taking molecular pathology into a new dimension.

Faratian D, Clyde RG, Crawford JW, Harrison DJ.

Nat Rev Clin Oncol. 2009 Aug;6(8):455-64. doi: 10.1038/nrclinonc.2009.102. Epub 2009 Jul 7. Review.

PMID:
19581910
47.
48.

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS.

Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17.

49.

Pleural Wegener's granulomatosis: a rare presentation.

Faratian D, Marr B, Böllert F, Luqmani R, Salter D, Wallace W.

Histopathology. 2009 Feb;54(3):391-3. doi: 10.1111/j.1365-2559.2009.03229.x. No abstract available.

PMID:
19236522
50.

Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.

Faratian D, Munro A, Twelves C, Bartlett JM.

Histopathology. 2009 Jan;54(2):254-7. doi: 10.1111/j.1365-2559.2008.03191.x.

PMID:
19207951

Supplemental Content

Loading ...
Support Center